Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Janssen Pharmaceutica N.V. - Targeted therapy optimising the future of GU cancer care – realising the value, exploring the evidence

Revolutionising urothelial carcinoma care: Discovering the value of targeted therapy

Date

20 Oct 2023

Session

Janssen Pharmaceutica N.V. - Targeted therapy optimising the future of GU cancer care – realising the value, exploring the evidence

Topics

Genetic and Genomic Testing

Tumour Site

Urothelial Cancer

Presenters

Guillermo Antonio De Velasco Oria

Authors

G.A. De Velasco Oria

Author affiliations

  • Medical Oncology Department, Hospital Universitario 12 de Octubre, 28041 - Madrid/ES

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.